9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
99 hedge funds and large institutions have $81.7M invested in 9 Meters Biopharma in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 25 closing their positions.
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
10% more funds holding
Funds holding: 90 → 99 (+9)
8% less capital invested
Capital invested by funds: $88.6M → $81.7M (-$6.91M)
15% less call options, than puts
Call options by funds: $2.56M | Put options by funds: $3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.73M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.65M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.53M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$21.1M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$7.77M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.5M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.73M |
| 5 |
Citigroup
New York
|
-$963K |
NMTR Hedge Fund Activity: Q2 2021 in Review
99 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2021, worth a combined $81.7M — down 7.8% from $88.6M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new NMTR positions and 25 closed out — a net gain of 9 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $11.9M. The largest seller was OrbiMed, cutting an estimated $21.1M.
- 99 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2021, up from 90 in Q1 2021.
- Funds reported $81.7M of 9 Meters Biopharma stock for Q2 2021, down 7.8% quarter-over-quarter.
- 34 funds opened new 9 Meters Biopharma positions in Q2 2021 and 25 closed out, a net change of +9 holders.
- The largest 9 Meters Biopharma buyer in Q2 2021 was BlackRock, an estimated $11.9M added.
- The largest 9 Meters Biopharma seller in Q2 2021 was OrbiMed, an estimated $21.1M sold.
Based on aggregated 13F filings for Q2 2021.